Evidence map›Paper›PMID 35524791›Full record

ArticleCancer immunology, immunotherapy : CII2022

Targeting tumor extracellular matrix activates the tumor-draining lymph nodes.

Alexander J Najibi, Ting-Yu Shih, David K Y Zhang, Junzhe Lou, Miguel C Sobral, Hua Wang, Maxence O Dellacherie, Kwasi Adu-Berchie, David J Mooney

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alexander J NajibiJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Ting-Yu ShihJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
David K Y ZhangJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Junzhe LouJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Miguel C SobralJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Hua WangJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Maxence O DellacherieJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
Kwasi Adu-BerchieJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA.
David J MooneyJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA. mooneyd@seas.harvard.edu.ORCID http://orcid.org/0000-0001-6299-1194
Harvard University · USBoston University · US

Funding

iPSC-derived Repair-Responsive Fibroblasts to Heal Diabetic Foot UlcersR01DK098055 · NIDDK · TUFTS UNIVERSITY BOSTON · PI GARLICK, JONATHAN A · 2012 to 2015
$2.6M
Biomaterial Cancer Vaccines that Generate Patient-Specific Antigen In SituR01CA223255 · NCI · HARVARD UNIVERSITY · PI MOONEY, DAVID J · 2018 to 2022
$2.1M
Biomaterial based breast cancer vaccineR01EB015498 · NIBIB · HARVARD MEDICAL SCHOOL · PI MOONEY, DAVID J · 2013 to 2016
$1.5M
NCI NIH HHS R01 CA223255NIH HHS R01 CA223255NIH HHS R01 DK098055NIH HHS R01 EB015498
6 · The paper itself

Abstract

Disruption of the tumor extracellular matrix (ECM) may alter immune cell infiltration into the tumor and antitumor T cell priming in the tumor-draining lymph nodes (tdLNs). Here, we explore how intratumoral enzyme treatment (ET) of B16 melanoma tumors with ECM-depleting enzyme hyaluronidase alters adaptive and innate immune populations, including T cells, DCs, and macrophages, in the tumors and tdLNs. ET increased CD103

Indexed as

Cancer VaccinesMelanoma, ExperimentalAnimalsAntigens, NeoplasmCryogelsDendritic CellsExtracellular MatrixHumansHyaluronoglucosaminidaseLymph NodesOvalbuminAntigens, NeoplasmCancer VaccinesCryogelsHyaluronoglucosaminidaseOvalbuminAdaptive immunityCancer vaccineTumor-draining lymph nodesTumor extracellular matrix

Identifiers

PMID35524791
PMCPMC10992058
OpenAlexW4229015509

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.